SCHEMBL20163033

SCHEMBL20163033

CC(C)(C)OC(=O)NN(C(=O)c1nc(N2CCN(C(=O)OC(C)(C)C)CC2)cs1)c1cccc(-c2ccoc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
CKS1B P61024 2/20 0.40
SKP1 P63208 2/20 0.40
SKP2 Q13309 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
ACHE P22303 2/20 0.36
ABCB1 P08183 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
WNT3A P56704 1/20 0.35
KIT P10721 1/20 0.35
GBA1 P04062 1/20 0.35
ACKR3 P25106 2/20 0.35
JAK2 O60674 1/20 0.34
JAK3 P52333 1/20 0.34
LRRK2 Q5S007 1/20 0.34
BACE1 P56817 1/20 0.34
ADORA2A P29274 1/20 0.34
PRMT5 O14744 1/20 0.34
ALK Q9UM73 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20163127 0.90 CKS1B (0.41) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL20163018 0.89 ABCB1 (0.45) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL20163121 0.87 HDAC2 (0.42) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL20163076 0.86 GPR119 (0.41) GPR119CKS1BSKP1SKP2ACHE
SCHEMBL20163099 0.85 CKS1B (0.43) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL20163029 0.85 GPR119 (0.44) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL20163147 0.83 GPR119 (0.42) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL20163023 0.83 HDAC2 (0.40) GPR119CKS1BSKP1SKP2HDAC1
SCHEMBL20163052 0.82 HDAC3 (0.43) GPR119CKS1BSKP1SKP2HDAC2
SCHEMBL28314027 0.80 HDAC2 (0.49) HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-01-03 US disclosed
US-20200377465-A1 SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2020-12-03 US disclosed
US-10774056-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. (US) 2020-09-15 US disclosed
US-20190330169-A1 SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2019-10-31 US disclosed
EP-3544969-A1 PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS Regenacy Pharmaceuticals, LLC (US) 2019-10-02 EP disclosed
US-10385031-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2019-08-20 US disclosed
WO-2018098296-A1 PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC (US) 2018-05-31 WO disclosed
US-20180141923-A1 SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385031-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 GPR119 1458/4885CKS1B 366/4885SKP1 1856/4885
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 GPR119 1354/4885CKS1B 363/4885SKP1 1658/4885
US-20180141923-A1 SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 GPR119 1560/4885CKS1B 246/4885SKP1 1802/4885
US-10774056-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 GPR119 2449/4885CKS1B 573/4885SKP1 1022/4885
US-20200377465-A1 SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 GPR119 1880/4885CKS1B 436/4885SKP1 1189/4885
US-20190330169-A1 SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 GPR119 1560/4885CKS1B 246/4885SKP1 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.